Pfizer (NYSE:PFE) has been assigned a $39.00 price target by equities researchers at Jefferies Group in a report released on Monday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Jefferies Group’s price target indicates a potential upside of 5.98% from the stock’s current price.
Other research analysts have also recently issued research reports about the company. Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Goldman Sachs Group set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. UBS Group set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. BMO Capital Markets set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Finally, Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $39.40.
Pfizer (NYSE PFE) opened at $36.80 on Monday. Pfizer has a one year low of $31.67 and a one year high of $39.43. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $219,350.00, a price-to-earnings ratio of 21.03, a PEG ratio of 2.05 and a beta of 0.94.
Pfizer announced that its board has approved a share repurchase plan on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board believes its shares are undervalued.
In other Pfizer news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,260 shares of company stock valued at $899,987. 0.06% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in shares of Pfizer by 2.8% in the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after acquiring an additional 12,183,218 shares during the period. Mackenzie Financial Corp boosted its stake in shares of Pfizer by 29,164.7% in the fourth quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock worth $415,878,000 after acquiring an additional 11,442,753 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Pfizer by 243.5% in the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after acquiring an additional 9,339,749 shares during the period. Vanguard Group Inc. boosted its stake in shares of Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares during the period. Finally, Amundi Pioneer Asset Management Inc. boosted its stake in shares of Pfizer by 81.3% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock worth $691,583,000 after acquiring an additional 8,563,358 shares during the period. 70.12% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Pfizer (PFE) Given a $39.00 Price Target by Jefferies Group Analysts” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3226784/pfizer-pfe-given-a-39-00-price-target-by-jefferies-group-analysts.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.